SCHEMBL7424140

SCHEMBL7424140

COC(=O)C1=C(C)NC(C)=C(C(=O)c2ccco2)C1c1ccccc1[N+](=O)[O-]

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 6/20 0.76
CYP1A2 P05177 6/20 0.76
MAPT P10636 6/20 0.76
CACNA1C Q13936 5/20 0.76
TSHR P16473 5/20 0.76
CYP3A4 P08684 5/20 0.76
CYP2C9 P11712 5/20 0.76
CYP2C19 P33261 5/20 0.76
KMT2A Q03164 4/20 0.76
KDM4E B2RXH2 4/20 0.76
LMNA P02545 3/20 0.76
NFKB1 P19838 3/20 0.76
ALDH1A1 P00352 3/20 0.76
HPGD P15428 3/20 0.76
HSD17B10 Q99714 3/20 0.76
ABCC4 O15439 2/20 0.76
CACNA1F O60840 2/20 0.76
ABCB11 O95342 2/20 0.76
ADORA2A P29274 2/20 0.76
ADORA1 P30542 2/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10885876 0.90 CACNA1D (0.60) ADORA3CYP1A2MAPTCACNA1CTSHR
Nifedipine SCHEMBL1172946 0.87 ADORA3 (1.00) ADORA3CYP1A2MAPTCACNA1CTSHR
Nifedipine SCHEMBL29349595 0.87 ADORA3 (1.00) ADORA3CYP1A2MAPTCACNA1CTSHR
Nifedipine SCHEMBL3968 0.87 ADORA3 (1.00) ADORA3CYP1A2MAPTCACNA1CTSHR
Nifedipine SCHEMBL3858071 0.86 ADORA3 (0.97) ADORA3CYP1A2MAPTCACNA1CTSHR
Nifedipine SCHEMBL8851397 0.86 ADORA3 (0.97) ADORA3CYP1A2MAPTCACNA1CTSHR
Nifedipine SCHEMBL5694031 0.86 ADORA3 (0.97) ADORA3CYP1A2MAPTCACNA1CTSHR
Nifedipine SCHEMBL8851402 0.86 ADORA3 (0.97) ADORA3CYP1A2MAPTCACNA1CTSHR
Nifedipine SCHEMBL27076589 0.86 ADORA3 (0.97) ADORA3CYP1A2MAPTCACNA1CTSHR
Nifedipine SCHEMBL27076587 0.86 ADORA3 (0.97) ADORA3CYP1A2MAPTCACNA1CTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0301133-A2 Long acting formulation SYNTEX (U.S.A.) INC. (US) 1989-02-01 EP claimed
EP-0124777-B1 1,4-DIHYDROPYRIDINE DERIVATIVES MERRELL DOW PHARMACEUTICALS INC. (US) 1986-10-29 EP claimed
US-4529733-A Substituted in position 4 with a 2-nitrophenyl compound MERRELL DOW PHARMACEUTICALS INC. (US) 1985-07-16 US claimed
EP-0124777-A1 1,4-Dihydropyridine derivatives MERRELL DOW PHARMACEUTICALS INC. (US) 1984-11-14 EP claimed
US-5209933-A A dihydropyridine compound SYNTEX (U.S.A.) INC. (US) 1993-05-11 US disclosed
US-5198226-A Sustained release SYNTEX (U.S.A.) INC. (US) 1993-03-30 US disclosed
US-4940556-A SUSTAINED RELEASE OF CALCIUM CHANNEL BLOCKERS SYNTEX (U.S.A.) INC. (US) 1990-07-10 US disclosed
EP-0301133-A2 Long acting formulation SYNTEX (U.S.A.) INC. (US) 1989-02-01 EP disclosed
EP-0124777-B1 1,4-DIHYDROPYRIDINE DERIVATIVES MERRELL DOW PHARMACEUTICALS INC. (US) 1986-10-29 EP disclosed
US-4529733-A Substituted in position 4 with a 2-nitrophenyl compound MERRELL DOW PHARMACEUTICALS INC. (US) 1985-07-16 US disclosed
EP-0124777-A1 1,4-Dihydropyridine derivatives MERRELL DOW PHARMACEUTICALS INC. (US) 1984-11-14 EP disclosed